These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 18668587

  • 1. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    Kay J, High WA.
    Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [Abstract] [Full Text] [Related]

  • 3. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
    Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taïeb A.
    Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
    [Abstract] [Full Text] [Related]

  • 4. Is imatinib mesylate a promising drug in systemic sclerosis?
    van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM.
    Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
    [Abstract] [Full Text] [Related]

  • 5. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
    Distler JH, Manger B, Spriewald BM, Schett G, Distler O.
    Arthritis Rheum; 2008 Aug; 58(8):2538-42. PubMed ID: 18668536
    [Abstract] [Full Text] [Related]

  • 6. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial.
    Elmholdt TR, Buus NH, Ramsing M, Olesen AB.
    J Eur Acad Dermatol Venereol; 2013 Jun; 27(6):779-84. PubMed ID: 22188390
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y, Gottlieb AB.
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model.
    Hope TA, Leboit PE, High WA, Fu Y, Brasch RC.
    Magn Reson Imaging; 2013 Jan; 31(1):139-44. PubMed ID: 22898683
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A, Cario-André M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taïeb A.
    Dermatology; 2008 Jan; 216(2):109-17. PubMed ID: 18216472
    [Abstract] [Full Text] [Related]

  • 12. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J.
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH, Distler O.
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
    Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I.
    Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
    [Abstract] [Full Text] [Related]

  • 15. Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis.
    Elmholdt TR, Pedersen M, Jørgensen B, Ramsing M, Olesen AB.
    Acta Derm Venereol; 2011 Jun; 91(4):478-9. PubMed ID: 21537826
    [No Abstract] [Full Text] [Related]

  • 16. Imatinib in the treatment of nephrogenic systemic fibrosis.
    Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA.
    Am J Kidney Dis; 2009 Jan; 53(1):129-32. PubMed ID: 19012999
    [Abstract] [Full Text] [Related]

  • 17. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC, Technau K, Müller AM, Lübbert M, Bruckner-Tuderman L.
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
    Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK.
    Ann Rheum Dis; 2011 Jun; 70(6):1003-9. PubMed ID: 21398330
    [Abstract] [Full Text] [Related]

  • 19. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
    Taïeb A, Constans J, Mahon FX.
    Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
    [No Abstract] [Full Text] [Related]

  • 20. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Cohen MH, Farrell A, Justice R, Pazdur R.
    Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.